What is the current market valuation of the Single-Photon Emission Computed Tomography Market?

As of 2024, the market valuation stands at 1710.43 USD Million. Read More

What is the projected market size for the Single-Photon Emission Computed Tomography Market by 2035?

The market is expected to reach a valuation of 3564.11 USD Million by 2035. Read More

Which application segments are driving growth in the Single-Photon Emission Computed Tomography Market?

Key application segments include Oncology, with a valuation range of 450.0 to 950.0 USD Million, and Cardiology, ranging from 300.0 to 650.0 USD Million. Read More

What are the primary end-use segments in the Single-Photon Emission Computed Tomography Market?

The primary end-use segments are Hospitals, valued between 600.0 and 1200.0 USD Million, and Diagnostic Imaging Centers, ranging from 400.0 to 800.0 USD Million. Read More

How does the technology segment contribute to the Single-Photon Emission Computed Tomography Market?

The technology segment includes Hybrid Imaging, valued at 600.0 to 1200.0 USD Million, and Standalone Systems, which range from 400.0 to 800.0 USD Million. Read More

What tracer types are utilized in the Single-Photon Emission Computed Tomography Market?

Tracer types include Technetium-99m, with a valuation range of 800.0 to 1700.0 USD Million, and Iodine-123, ranging from 300.0 to 600.0 USD Million. Read More

What patient demographics are represented in the Single-Photon Emission Computed Tomography Market?

The market includes segments for Pediatric patients, valued between 1710.43 and 3564.11 USD Million, and Adult patients, ranging from 1026.26 to 2180.0 USD Million. Read More

Who are the key players in the Single-Photon Emission Computed Tomography Market?

Key players include GE Healthcare, Siemens Healthineers, and Philips Healthcare, among others. Read More

What trends are influencing the Single-Photon Emission Computed Tomography Market?

Trends include advancements in imaging technology and increasing demand for diagnostic imaging in various medical fields. Read More

Single-Photon Emission CT Market

Q: What is the expected CAGR for the Single-Photon Emission Computed Tomography Market during the forecast period?

The market is projected to grow at a CAGR of 6.9% from 2025 to 2035. Read More

ID: MRFR/HC/5764-HCR

90 Pages

Vikita Thakur

Last Updated: May 15, 2026

Single-Photon Emission Computed Tomography Market Research Report: Size, Share, Trend Analysis By Types (Hybrid SPECT Systems and Standalone SPECT Systems), Application (Oncology, Cardiology, and Neurology), End-User (Hospitals, Diagnostic Imaging Centers), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Million) | |
  1. 4.1.1 Cardiology | |
  2. 4.1.2 Oncology | |
  3. 4.1.3 Neurology | |
  4. 4.1.4 Infectious Diseases | |
  5. 4.1.5 Orthopedics |
2. 4.2 Healthcare, BY End Use (USD Million) | |
  1. 4.2.1 Hospitals | |
  2. 4.2.2 Diagnostic Imaging Centers | |
  3. 4.2.3 Research Institutions | |
  4. 4.2.4 Ambulatory Surgical Centers |
3. 4.3 Healthcare, BY Technology (USD Million) | |
  1. 4.3.1 Hybrid Imaging | |
  2. 4.3.2 Standalone Systems | |
  3. 4.3.3 Digital Imaging | |
  4. 4.3.4 Analog Imaging |
4. 4.4 Healthcare, BY Tracer Type (USD Million) | |
  1. 4.4.1 Technetium-99m | |
  2. 4.4.2 Iodine-123 | |
  3. 4.4.3 Gallium-68 | |
  4. 4.4.4 Fluorine-18 |
5. 4.5 Healthcare, BY Patient Type (USD Million) | |
  1. 4.5.1 Pediatric | |
  2. 4.5.2 Adult | |
  3. 4.5.3 Geriatric |
6. 4.6 Healthcare, BY Region (USD Million) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 GE Healthcare (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Siemens Healthineers (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Philips Healthcare (NL) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Canon Medical Systems (JP) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Elekta (SE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Medtronic (IE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Hitachi Medical Corporation (JP) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Nuclear Imaging (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY END USE |
8. 6.5 US MARKET ANALYSIS BY TECHNOLOGY |
9. 6.6 US MARKET ANALYSIS BY TRACER TYPE |
10. 6.7 US MARKET ANALYSIS BY PATIENT TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY END USE |
13. 6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY |
14. 6.11 CANADA MARKET ANALYSIS BY TRACER TYPE |
15. 6.12 CANADA MARKET ANALYSIS BY PATIENT TYPE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY END USE |
19. 6.16 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
20. 6.17 GERMANY MARKET ANALYSIS BY TRACER TYPE |
21. 6.18 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
22. 6.19 UK MARKET ANALYSIS BY APPLICATION |
23. 6.20 UK MARKET ANALYSIS BY END USE |
24. 6.21 UK MARKET ANALYSIS BY TECHNOLOGY |
25. 6.22 UK MARKET ANALYSIS BY TRACER TYPE |
26. 6.23 UK MARKET ANALYSIS BY PATIENT TYPE |
27. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION |
28. 6.25 FRANCE MARKET ANALYSIS BY END USE |
29. 6.26 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
30. 6.27 FRANCE MARKET ANALYSIS BY TRACER TYPE |
31. 6.28 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
32. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION |
33. 6.30 RUSSIA MARKET ANALYSIS BY END USE |
34. 6.31 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
35. 6.32 RUSSIA MARKET ANALYSIS BY TRACER TYPE |
36. 6.33 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
37. 6.34 ITALY MARKET ANALYSIS BY APPLICATION |
38. 6.35 ITALY MARKET ANALYSIS BY END USE |
39. 6.36 ITALY MARKET ANALYSIS BY TECHNOLOGY |
40. 6.37 ITALY MARKET ANALYSIS BY TRACER TYPE |
41. 6.38 ITALY MARKET ANALYSIS BY PATIENT TYPE |
42. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION |
43. 6.40 SPAIN MARKET ANALYSIS BY END USE |
44. 6.41 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
45. 6.42 SPAIN MARKET ANALYSIS BY TRACER TYPE |
46. 6.43 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY END USE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY TRACER TYPE |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY APPLICATION |
54. 6.51 CHINA MARKET ANALYSIS BY END USE |
55. 6.52 CHINA MARKET ANALYSIS BY TECHNOLOGY |
56. 6.53 CHINA MARKET ANALYSIS BY TRACER TYPE |
57. 6.54 CHINA MARKET ANALYSIS BY PATIENT TYPE |
58. 6.55 INDIA MARKET ANALYSIS BY APPLICATION |
59. 6.56 INDIA MARKET ANALYSIS BY END USE |
60. 6.57 INDIA MARKET ANALYSIS BY TECHNOLOGY |
61. 6.58 INDIA MARKET ANALYSIS BY TRACER TYPE |
62. 6.59 INDIA MARKET ANALYSIS BY PATIENT TYPE |
63. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION |
64. 6.61 JAPAN MARKET ANALYSIS BY END USE |
65. 6.62 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
66. 6.63 JAPAN MARKET ANALYSIS BY TRACER TYPE |
67. 6.64 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY END USE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY TRACER TYPE |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION |
74. 6.71 MALAYSIA MARKET ANALYSIS BY END USE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
76. 6.73 MALAYSIA MARKET ANALYSIS BY TRACER TYPE |
77. 6.74 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
78. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION |
79. 6.76 THAILAND MARKET ANALYSIS BY END USE |
80. 6.77 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
81. 6.78 THAILAND MARKET ANALYSIS BY TRACER TYPE |
82. 6.79 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
83. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION |
84. 6.81 INDONESIA MARKET ANALYSIS BY END USE |
85. 6.82 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
86. 6.83 INDONESIA MARKET ANALYSIS BY TRACER TYPE |
87. 6.84 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION |
89. 6.86 REST OF APAC MARKET ANALYSIS BY END USE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
91. 6.88 REST OF APAC MARKET ANALYSIS BY TRACER TYPE |
92. 6.89 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION |
95. 6.92 BRAZIL MARKET ANALYSIS BY END USE |
96. 6.93 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
97. 6.94 BRAZIL MARKET ANALYSIS BY TRACER TYPE |
98. 6.95 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
99. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION |
100. 6.97 MEXICO MARKET ANALYSIS BY END USE |
101. 6.98 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
102. 6.99 MEXICO MARKET ANALYSIS BY TRACER TYPE |
103. 6.100 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION |
105. 6.102 ARGENTINA MARKET ANALYSIS BY END USE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
107. 6.104 ARGENTINA MARKET ANALYSIS BY TRACER TYPE |
108. 6.105 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRACER TYPE |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY END USE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY TRACER TYPE |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY END USE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY TRACER TYPE |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION |
126. 6.123 REST OF MEA MARKET ANALYSIS BY END USE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
128. 6.125 REST OF MEA MARKET ANALYSIS BY TRACER TYPE |
129. 6.126 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
138. 6.135 HEALTHCARE, BY END USE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million) |
140. 6.137 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million) |
142. 6.139 HEALTHCARE, BY TRACER TYPE, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY TRACER TYPE, 2024 TO 2035 (USD Million) |
144. 6.141 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Million) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.2.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.2.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.2.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.3.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.3.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.3.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.4.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.4.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.4.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.5.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.5.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.5.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.6.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.6.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.6.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.7.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.7.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.7.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.8.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.8.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.8.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.9.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.9.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.9.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.10.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.10.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.10.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.11.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.11.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.11.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.12.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.12.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.12.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.13.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.13.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.13.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.14.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.14.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.14.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.15.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.15.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.15.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.16.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.16.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.16.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.17.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.17.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.17.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.18.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.18.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.18.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.19.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.19.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.19.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.20.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.20.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.20.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.21.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.21.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.21.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.22.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.22.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.22.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.23.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.23.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.23.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.24.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.24.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.24.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.25.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.25.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.25.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.26.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.26.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.26.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.27.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.27.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.27.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.28.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.28.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.28.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.29.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.29.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.29.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.30.2 BY END USE, 2025-2035 (USD Million) | |
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  4. 7.30.4 BY TRACER TYPE, 2025-2035 (USD Million) | |
  5. 7.30.5 BY PATIENT TYPE, 2025-2035 (USD Million) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Single-Photon Emission Computed Tomography Market Segmentation

Single-Photon Emission Computed Tomography Market By Application (USD Million, 2025-2035)

Cardiology
Oncology
Neurology
Infectious Diseases
Orthopedics

Single-Photon Emission Computed Tomography Market By End Use (USD Million, 2025-2035)

Hospitals
Diagnostic Imaging Centers
Research Institutions
Ambulatory Surgical Centers

Single-Photon Emission Computed Tomography Market By Technology (USD Million, 2025-2035)

Hybrid Imaging
Standalone Systems
Digital Imaging
Analog Imaging

Single-Photon Emission Computed Tomography Market By Tracer Type (USD Million, 2025-2035)

Technetium-99m
Iodine-123
Gallium-68
Fluorine-18

Single-Photon Emission Computed Tomography Market By Patient Type (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035